Summit Clinical Research s.r.o. — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

Summit Clinical Research s.r.o.

Location

Bratislava, Slovakia

Identifier

ORG-100046027

Address

Nove Mesto, Bardosova 2a, 831 01, Slovakia

Departments

-
Clinical Trial Unit
Department of Internal Medicine and Clinical Pharmacology
N/A
NA
Not applicable
Zariadenie biomedicinskeho vyskumu
Zariadenie biomedicínskeho výskumu (vnútorné lekárstvo, klinická farmakológia)

Clinical trials at this site (10)

Search interface

PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION Recruiting

2025-523641-10-00 Healthy / hepatic impaired volunteers only study to ass 3 2026-05-18
A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced live… Recruiting

2025-521647-20-00 hepatic impairment 3 2026-05-12
A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment Recruiting

2025-521947-19-00 Healthy, Hepatic Insufficiency 3 2025-11-19
Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended

2024-516293-29-01 Acute myeloid lymphoma (AML), myelodysplastic syndrome 4 2022-03-17
Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment Ended

2024-516292-33-00 Myelodysplastic syndrome (MDS) 3 2021-10-22
A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656,… Ended

2023-508270-29-01 Hepatic Impairment 3 2024-09-24
A Study About Fazirsiran in People With and Without Liver Problems. Ended

2023-503735-17-00 Hepatic impairment. 3 2023-10-05
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post-menopausal … Ended

2022-502277-41-00 moderate or severe hepatic impairment 3 2023-06-05
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/… Ended

2024-516455-40-00 Advanced liver fibrosis and/or mild liver cirrhosis 3 2023-05-25
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Liver Impairment With Advanced solid tumors or hematological malignancies Ended

2024-517141-13-00 Advanced solid tumors, or hematological malignancies an 3 2020-10-07